LRRK2 and Parkinson disease: Althoughremarkable investment has been devoted to many clinical trials toadvance potential disease-modifying therapeutic intervention, theunderlying disease mechanisms of PD still remain unclear, leadingto significant clinical attrition.1,2 In past decades,several proteins have been identified for possible involvement inthe pathogenesis of PD, and among them, leucine-rich repeat kinase2 (LRRK2) represents a highly potential target.3−5 Indeed, LRRK2mutations, which are autosomal dominant, represent the most commonknown cause of PD worldwide.